Steven Edland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2947276/publications.pdf

Version: 2024-02-01

430874 434195 1,501 37 18 31 citations h-index g-index papers 43 43 43 2844 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.8	310
2	NPTX2 and cognitive dysfunction in Alzheimer's Disease. ELife, 2017, 6, .	6.0	146
3	Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer's Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells. Cell Stem Cell, 2015, 16, 373-385.	11.1	143
4	Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology, 2016, 86, 1000-1008.	1.1	141
5	Pulse Pressure in Relation to Tau-Mediated Neurodegeneration, Cerebral Amyloidosis, and Progression to Dementia in Very Old Adults. JAMA Neurology, 2015, 72, 546.	9.0	101
6	Concepts for brain aging: resistance, resilience, reserve, and compensation. Alzheimer's Research and Therapy, 2019, 11, 22.	6.2	81
7	ADCS Prevention Instrument Project: Overview and Initial Results. Alzheimer Disease and Associated Disorders, 2006, 20, S109-S123.	1.3	60
8	Power Calculations for Clinical Trials in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 369-377.	2.6	59
9	Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 72-78.	2.2	49
10	Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients. MBio, 2018, 9, .	4.1	48
11	Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 269-277.	1.3	42
12	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology, 2020, 94, e2076-e2087.	1.1	42
13	MClâ€toâ€normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 1322-1332.	0.8	37
14	Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 561-569.	0.8	25
15	Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharmaceutical Statistics, 2015, 14, 418-426.	1.3	24
16	Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions. Acta Neuropathologica, 2020, 139, 527-546.	7.7	23
17	NIA-Funded Alzheimer Centers Are More Efficient than Commercial Clinical Recruitment Sites for Conducting Secondary Prevention Trials of Dementia. Alzheimer Disease and Associated Disorders, 2010, 24, 159-164.	1.3	20
18	The net effect of alternative allocation ratios on recruitment time and trial cost. Clinical Trials, 2009, 6, 126-132.	1.6	19

#	Article	IF	CITATIONS
19	Smokers who report smoking but do not consider themselves smokers: a phenomenon in need of further attention: TableÂ1. Tobacco Control, 2015, 24, 400-403.	3.2	19
20	TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. Journal of Alzheimer's Disease, 2018, 66, 1549-1558.	2.6	16
21	Age-at-Onset and <i>APOE</i> -Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. Neurology, 2021, 96, e2272-e2283.	1.1	15
22	Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease. Neurobiology of Aging, 2019, 75, 169-177.	3.1	13
23	Smoking prevalence in urban and rural populations: findings from California between 2001 and 2012. American Journal of Drug and Alcohol Abuse, 2016, 42, 152-161.	2.1	10
24	Proof of concept demonstration of optimal composite MRI endpoints for clinical trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 177-181.	3.7	9
25	Sexâ€specific composite scales for longitudinal studies of incipient Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 508-514.	3.7	9
26	Association of Neurofibrillary Tangle Distribution With Age at Onset–Related Clinical Heterogeneity in Alzheimer Disease. Neurology, 2022, 98, .	1.1	9
27	Design of pilot studies to inform the construction of composite outcomeÂmeasures. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 213-218.	3.7	8
28	Sex and <i>APOE</i> É>4 modify the effect of cardiovascular risk on tau in cognitively normal older adults. Brain Communications, 2022, 4, fcac035.	3.3	8
29	The differential associations of preexisting conditions with trauma-related outcomes in the presence of competing risks. Injury, 2016, 47, 677-684.	1.7	7
30	Power formulas for mixed effects models with random slope and intercept comparing rate of change across groups. International Journal of Biostatistics, 2022, 18, 173-182.	0.7	4
31	Effects of Military Service on Marital Stability Among World War II U.S. Veterans of Japanese Descent. Military Medicine, 2018, 183, e525-e531.	0.8	3
32	F4-02-01: Evidence of learning or placebo effects relevant to clinical trials of mild cognitive impairment., 2013, 9, P676-P676.		0
33	F3-02-03: OPTIMALLY WEIGHTED ENDPOINTS FOR CLINICAL TRIALS IN MILD COGNITIVE IMPAIRMENT AND PRE-CLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P204-P204.		0
34	P1-209: Cerebral amyloid angiopathy is not associated with late-life cognitive performance in the honolulu asia aging study., 2015, 11, P430-P431.		0
35	P3â€007: Optimal Composite Volumetric MRI Endpoints in Longitudinal Studies of Neurodegenerative Disease: Proofâ€ofâ€Concept Demonstration in Primary Progressive Aphasia. Alzheimer's and Dementia, 2016, 12, P820.	0.8	0
36	P3â€331: LIFETIME ALCOHOL INTAKE IS ASSOCIATED WITH AGINGâ€RELATED COGNITIVE DECLINE: THE HONOLULUâ€ASIA AGING STUDY (HAAS). Alzheimer's and Dementia, 2018, 14, P1207.	0.8	0

3

#	Article	IF	CITATIONS
37	Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. Pharm Stat. 18 (2):239â€47, 2019, DOI: 10.1002/pst.1920. Pharmaceutical Statistics, 2020, 19, 492-493.	1.3	O